(STELLAR-311) Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Cancers (STELLAR-311)

IDENTIFIER (ClinicalTrials.gov): NCT06943755

DRUG/TREATMENT: Zanzalintinib and Everolimus

PHASE: 2/3

STATUS: Recruiting

SPONSOR: Exelixis

DESCRIPTION:

A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors. 

The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.

For more information on eligibility criteria, trial locations, study details, etc., go to STELLAR-311 Clinical Trial (Exelixis) and/or ClinicalTrials.gov to view this trial here.

CONTACT: 

Exelixis Clinical Trials, STELLAR-311 Clinical Trial (Exelixis)

EMAIL:  druginfo@exelixis.com 

PHONE: 1-888-EXELIXIS (888-393-5494)

This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information. 

OTHER HELPFUL RESOURCES:

This Exelixis study site STELLAR-311 Clinical Trial (Exelixis) includes a toll-free medical information hotline, information on the study and eligibility criteria and study sites *Please note, Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials.